Content about Pharmacology

October 28, 2010

The Food and Drug Administration has approved a new drug for treating schizophrenia, the agency...

SILVER SPRING, Md. The Food and Drug Administration has approved a new drug for treating schizophrenia, the agency said Thursday.

The FDA announced the approval of Latuda (lurasidone hydrochloride), made by Fort Lee, N.J.-based Sunovion Pharmaceuticals. The drug is approved to treat adults with the disease, a mental illness that causes hallucinations, delusions, paranoia and disordered thinking and behavior.

October 28, 2010

Vivus found itself foiled in its efforts to market a drug for obesity as the...

MOUNTAIN VIEW, Calif. Vivus found itself foiled in its efforts to market a drug for obesity as the Food and Drug Administration turned down its regulatory approval application.

 

October 27, 2010

Risks of counterfeiting, contamination and intellectual property theft could increase with the globalization of the...

NEW YORK Risks of counterfeiting, contamination and intellectual property theft could increase with the globalization of the pharmaceutical supply chain, according to a new report.

October 26, 2010

The charitable arm of the National Association of Chain Drug Stores announced its $1 million...

ALEXANDRIA, Va. The charitable arm of the National Association of Chain Drug Stores announced its $1 million contribution to the National Consumers League's medication adherence awareness campaign.

 

October 25, 2010

Actavis last week recalled 18 lots of its patches designed to treat persistent, moderate to...

MORRISTOWN, N.J. Actavis last week recalled 18 lots of its patches designed to treat persistent, moderate to severe chronic pain.

October 24, 2010

Health care’s lumbering shift to electronic prescribing and health information technology has been a long...

October 24, 2010

More than a quarter trillion dollars in pharmaceutical sales happened through primary healthcare distributors in...

October 24, 2010

The Food and Drug Administration has approved risk evaluation and mitigation strategies for two sleep...

FRAZER, Pa. The Food and Drug Administration has approved risk evaluation and mitigation strategies for two sleep disorder drugs made by Cephalon, the drug maker said.

 

Cephalon announced that the FDA approved the REMS for Nuvigil (armodafinil) and Provigil (modafinil), both used to improve wakefulness in patients with sleep apnea, narcolepsy or shift work disorder.

 

 

October 24, 2010

Independent pharmacies in 2009 generally were able to withstand the pummeling of a major recession,...

October 24, 2010

Some say it cheapens patient care and reduces quality. The nation’s fourth-biggest pharmacy retailer and...

October 20, 2010

K-V Pharmaceutical has created a new marketing subsidiary for generic drugs, the company said Wednesday....

ST. LOUIS K-V Pharmaceutical has created a new marketing subsidiary for generic drugs, the company said Wednesday.

 

K-V announced the establishment of Nesher Pharmaceuticals, appointing as its president Mark Hartman, who has had several positions in generic drug companies.

 

 

October 20, 2010

The Food and Drug Administration could decide that some generic drugs are not equivalent to...

BETHESDA, Md. The Food and Drug Administration could decide that some generic drugs are not equivalent to their branded counterparts, according to published reports.

 

October 19, 2010

The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli...

INDIANAPOLIS The Food and Drug Administration declined to approve a long-anticipated diabetes drug made by Eli Lilly and two other companies, the companies said Tuesday.

Lilly, Amylin Pharmaceuticals and Alkermes said the FDA issued them a complete response letter for their application for Bydureon (exenatide), a once-weekly version of the Type 2 diabetes drug Byetta. A complete response letter means that the FDA has completed review of a regulatory application, but issues remain that preclude approval.

 

October 19, 2010

A drug store chain and a leading provider of mobile drug reference tools and interactive...

October 18, 2010

It’s a ruling that could bolster the retail pharmacy industry’s long campaign to extend full...

October 18, 2010

The Food and Drug Administration has approved a drug for treating insomnia made by Actavis,...

MORRISTOWN, N.J. The Food and Drug Administration has approved a drug for treating insomnia made by Actavis, the generic drug maker said Monday.

 

Actavis announced the approval of zolpidem tartrate extended-release tablets in the 6.25-mg strength. The company has begun shipping the drug.

 

 

The drug is a generic version of Sanofi-Aventis’ Ambien CR, which had sales of around $129 million during the 12-month period ended in June, according to IMS Health.

 

October 18, 2010

October is American Pharmacists Month, and Kinney Drugs has spent it educating patients about the...

October 18, 2010

The National Association of Chain Drug Stores on Tuesday released a letter addressed to the...

October 18, 2010

Drug maker Purdue Pharma has donated $200,000 to the National Association of State Controlled Substances...

CHARLESTON, S.C. Drug maker Purdue Pharma has donated $200,000 to the National Association of State Controlled Substances Authorities to address the abuse of prescription drugs, NASCSA said Tuesday.

 

The grant, presented at the group’s annual conference in Charleston, S.C., is designed to support state prescription drug monitoring programs. The NASCSA will be in charge of distributing the money to state agencies. Purdue is the maker of OxyContin (oxycodone), a commonly abused prescription opioid painkiller.

 

 

October 17, 2010

Mission Skincare on Monday announced a new licensing agreement with Major Leagure Baseball Properties around...

NEW YORK Mission Skincare on Monday announced a new licensing agreement with Major Leagure Baseball Properties around its external analgesic Mission maximum-strength muscle rub.

October 14, 2010

Under a settlement reached with the Drug Enforcement Administration and the U.S. Attorneys' Offices for...

October 14, 2010

During the Academy of Managed Care Pharmacy 2010 Educational Conference held Oct. 13 to 15,...

WHAT IT MEANS AND WHY IT'S IMPORTANT During the Academy of Managed Care Pharmacy 2010 Educational Conference held Oct. 13 to 15, CVS Caremark shared data to further demonstrate ways to curb drug costs. This is important because what these studies, and others like it, continue to illustrate is that there are a variety of ways to reduce prescription drug costs beyond simply cutting prices to levels that could compromise a pharmacy's ability to deliver the high-quality service necessary to achieve better health outcomes.

October 14, 2010

When a patient isn’t showing a response to a medication, a common tactic the doctor...

BOSTON When a patient isn’t showing a response to a medication, a common tactic the doctor might use is to increase the dosage. According to a new study, however, the ineffectiveness might be happening because the patient isn’t properly taking the medication.

October 14, 2010

The Food and Drug Administration has approved a Watson Pharmaceuticals generic drug for treating high...

MORRISTOWN, N.J. The Food and Drug Administration has approved a Watson Pharmaceuticals generic drug for treating high blood pressure, Watson said Friday.

 

The company announced the FDA approval of amlodipine besylate and benazepril capsules in the 5/20-mg, 10/20-mg, 2.5/10-mg and 5/10-mg strengths.

 

 

The drug is a generic version of Novartis’ Lotrel. Branded and generic versions of the drug had sales of around $1.05 billion during the 12-month period ended in June, according to IMS Health.

 

October 13, 2010

Enactment by the White House of a landmark, pharmacy-friendly drug-disposal bill won quick praise from...

WASHINGTON Enactment by the White House of a landmark, pharmacy-friendly drug-disposal bill won quick praise from chain pharmacy leaders Thursday.

 

President Obama signed the Secure and Responsible Drug Disposal Act into law Wednesday, changing the way the Drug Enforcement Administration regulates the return and destruction of unused and unwanted higher-risk medications. The new law establishes a legal process by which consumers can return their lawfully obtained controlled substance medications to DEA-authorized entities for disposal.